<!DOCTYPE html>
{% load static %}
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport"
          content="width=device-width, user-scalable=no, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0">
    <meta http-equiv="X-UA-Compatible" content="ie=edge">
    <link rel="stylesheet" href="{% static 'css/base.css' %}">
    <img src="{% static 'pfizer-logo.png' %}">
    <title>Title</title>
</head>
<body>
<h1>A Phase 3 study of Drug A in patients with Diabetes mellitus</h1>
<div>
    <p> User: {{ user }} </p>
</div>
<div class="topnav">

    <a href="{% url 'index' %}">Home</a>
    {% if perms.CT_platform.view_patients %}
        <a href="{% url 'main_page' %}">Patients List</a>
    {% endif %}
    {% if perms.CT_platform.add_patients %}
        <a href="{% url 'add_patient' %}">Add Patient</a>
    {% endif %}
    {% if perms.CT_platform.view_drug %}
        <a href="{% url 'drug_list' %}">Drug List</a>
    {% endif %}
    {% if perms.CT_platform.add_drug %}
    <a href="{% url 'add_drug' %}">Add Drug</a>
    {% endif %}
     {% if perms.CT_platform.view_treatment %}
        <a href="{% url 'study_scheme_list' %}">CT Scheme List</a>
    {% endif %}
    {% if perms.CT_platform.add_treatment %}
        <a href="{% url 'add_study_scheme' %}">Add CT Scheme</a>
    {% endif %}
    {% if perms.Accounts.view_user %}
        <a href="{% url 'userlist' %}">Users</a>
    {% endif %}
    {% if user.is_authenticated %}
        {% if perms.Accounts.add_user %}
            <a href="{% url 'register' %}"> Register</a>
        {% endif %}
        <a href="{% url 'change_password' %}"> Change Password</a>
        <a href="{% url 'logout' %}"> Logout</a>
    {% else %}
        <a href="{% url 'login' %}"> Login</a>
    {% endif %}
</div>
<p>
    {% block template %}
        Clinical trial will include 40 diabetic patients(fasting glucose>5,5mmol/l and OGTT>7,8 mmol/l)
        in total, who will be randomly assigned into 1 out of  2 therapy arms with: reference drug or
        drug candidate A. Equal number of patients (20 patients) will be randomly
        allocated into each study group. The trial will be double-blinded, meaning that the drug will
        be encrypted by random: A or B labels and kept secret for employees in contact with patients. After
        patient registration and medical interview at day 0, the pills at the dose appropriate to
        patient's body weight will be issued by the pharmacist. The medical control visits will take
        place every 14 days during 70-day-long therapy scheme. The control follow-up visit should occur
        at least 1 year after the last dose. In preclinical studies the incidence of body weight loss
        and eyesight worsening were reported as the most common adverse events, those these parameters
        will be investigated during check-up visits.
    {% endblock %}
</p>
</body>
<footer class="footer-section pt-3 pb-3">
    <div class="container text-center">
        <p>Created by Piotr Chroscicki</p>
        <p>Copyright Â© 2022 Chroscicki Studio. All rights reserved.</p>
    </div>
    <div class="container text-center2">
        {{ actual_date }}
    </div>
</footer>
</html>